Ruby Vishnu Patel, MD
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Hospitals listed: Lucile Salter Packard Children'S Hsp at Stanford. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Patel’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A146426 · Current
Licensed to practise in California · since 2016 · expires 2028-05-31 · George Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lucile Salter Packard Children'S Hsp at StanfordPalo Alto, CAChildren · Voluntary non-profit - Private · No emergency departmentPart of Stanford Health Care, which runs 3 hospitalsNo overall ratingNo measure marked better or worse than the national rate
Original Medicare doctor bills
$11,819
Medicare paid this office $11,819 for 17 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
17 Original Medicare patients in 2024. Average age 15 · Health risk score 7.35. Sicker patients than 9 in 10 peers; the typical pediatric medicine clinician is at 1.4.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75%.
The office billed $49,050, Medicare allowed $15,035 and paid $11,819; for 107 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$43,659 in 2024
Medicaid paid $43,659 for 269 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 215 | $39,945 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 42 | $2,198 |
| Return visit (30+ min) | 12 | $1,516 |
| 2024 | 269 | 3 | 27 | $43,659 |
| 2023 | 407 | 3 | 35 | $47,598 |
| 2022 | 51 | 1 | 18 | $7,516 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 257 | $36,901 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 85 | $6,048 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 65 | $4,649 |
2022
| Long return visit (40+ min) | 51 | $7,516 |
Money from drug and device companies
$4,455 in 2025
| 2025 | 2 | 17 | $2,800 | $4,455 |
| 2024 | 2 | 14 | None | $1,596 |
| 2022 | 2 | 2 | None | $244 |
| 2020 | 1 | 1 | None | $31 |
| 2019 | 1 | 1 | None | $122 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Travere Therapeutics | Filspari | $4,222 | 10 payments
|
| Ascendis Pharma Endocrinology | Yorvipath | $232 | 7 payments
|
See all 17 published payments
| Ascendis Pharma Endocrinology | Meals · 2025-12-16 | Yorvipath | $23 |
| Travere Therapeutics | Meals · 2025-12-16 | None | $147 |
| Travere Therapeutics | Travel · 2025-12-16 | None | $169 |
| Travere Therapeutics | Consulting · 2025-12-16 | None | $2,800 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $32 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $32 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $62 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $71 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $124 |
| Travere Therapeutics | Travel · 2025-12-05 | Filspari | $315 |
| Travere Therapeutics | Travel · 2025-12-05 | Filspari | $470 |
| Ascendis Pharma Endocrinology | Meals · 2025-11-04 | Yorvipath | $23 |
| Ascendis Pharma Endocrinology | Meals · 2025-09-23 | Yorvipath | $21 |
| Ascendis Pharma Endocrinology | Meals · 2025-08-29 | Yorvipath | $14 |
| Ascendis Pharma Endocrinology | Meals · 2025-07-31 | None | $115 |
| Ascendis Pharma Endocrinology | Meals · 2025-07-10 | Yorvipath | $17 |
| Ascendis Pharma Endocrinology | Meals · 2025-05-21 | Yorvipath | $18 |
See earlier years (2024, 2022, 2020, 2019)
2024: $1,596
| Bayer Healthcare Pharmaceuticals | Kerendia | $1,471 | 13 payments
|
| Takeda Pharmaceuticals U.S.A. | Livtencity | $125 | 1 payment
|
2022: $244
| Alexion Pharmaceuticals | Ultomiris | $122 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $122 | 1 payment
|
2020: $31
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $31 | 1 payment
|
2019: $122
| Alexion Pharmaceuticals | Ultomiris | $122 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Bayer Healthcare Pharmaceuticals Inc. · Bay 948862, A 6-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety and Pk/Pd of An Age-and Body Weight-Adjusted Oral Finerenone Regimen, in Addition To An Acei Or Arb, for the Treatment of Children, 6 Mo · 2024 | Their institution | $62,159 |
| Bayer Healthcare Pharmaceuticals Inc. · A 6-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety and Pk/Pd of An Age-and Body Weight-Adjusted Oral Finerenone Regimen, in Addition To An Acei Or Arb, for the Treatment of Children, 6 Months To <1 · 2025 | Their institution | $25,560 |
Professional record
- NPI
- 1275927691
- Licence
- CA A146426California A146426: Current · expires 2028-05-31
- Trained
- George Washington University School of Medicine, 2015
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0210X (2080P0210X); Pediatrics (208000000X)
- Mailing address
- 453 Quarry Rd # Mc5660, Palo Alto, CA, 94304
- NPI first listed
- 2015-03-24
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 275 W Macarthur Blvd, Oakland, CA, 94611 · 300 Pasteur Dr, Palo Alto, CA, 94305 · 453 Quarry Rd # Mc5660, Palo Alto, CA, 94304